From AI to LMICs: Four global and regional trends impacting pharma P&MA
Published on June 6, 2025
td { padding:5px; } table li { margin-bottom:3px; }
What key pricing and market access (P&MA) developments should pharma leaders address today? How can you respond with confidence and steer your organization toward long-term advantage?
It is a new era for pharmaceutical P&MA. From policy reforms to digital advancements, these global and regional developments are shaping how pharmaceutical companies are engaging with their partners.
Yet, many organizations are still unprepared for these shifts, risking missed opportunities and long-term challenges. Through discussions with industry leaders, we have identified four critical developments impacting the P&MA function across the industry:
